{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:10:53Z","timestamp":1792239053497,"version":"4.4.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270235"],"award-info":[{"award-number":["82270235"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270234"],"award-info":[{"award-number":["82270234"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82341206"],"award-info":[{"award-number":["82341206"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Relapsed\/refractory T cell-derived malignancies present with high heterogeneity and poor prognoses. Recently, chimeric antigen receptor (CAR)-T cell therapy has shown remarkable safety and efficacy in the treatment of B cell-derived malignancies. However, the treatment of CAR-T cells in T cell-derived malignancies has more limitations, such as fratricide, T cell aplasia, and tumor contamination, mainly because of the similarity between normal and malignant T cells. Pan-T antigen CAR-T cells (such as CD5 and CD7 targets), the most widely used CAR-T cells in clinical trials, can cover almost all T cell-derived malignant cells but can also induce severe killing of CAR-T cells and normal T cells. Compared to autologous sources of CAR-T cells, allogeneic CAR-T cells can prevent tumor contamination and become universal products by gene-editing. However, none of these CAR-T cells could completely prevent immune deficiency and disease relapse after T-targeted CAR-T cell therapy. In this review, we summarize the current challenges of CAR-T cell therapy for T cell-derived malignancies in clinical practice and potential strategies to address these limitations.<\/jats:p>","DOI":"10.1186\/s40164-024-00584-6","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T11:38:46Z","timestamp":1732793926000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies"],"prefix":"10.1186","volume":"13","author":[{"given":"Haiqiong","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houli","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delin","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"issue":"9","key":"584_CR1","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1182\/blood-2017-01-741389","volume":"129","author":"LH Sehn","year":"2017","unstructured":"Sehn LH, Soulier J. Introduction to the review series on T-cell malignancies. Blood. 2017;129(9):1059\u201360.","journal-title":"Blood"},{"key":"584_CR2","doi-asserted-by":"publisher","first-page":"204062072211430","DOI":"10.1177\/20406207221143025","volume":"13","author":"L Luo","year":"2022","unstructured":"Luo L, Zhou X, Zhou L, Liang Z, Yang J, Tu S, et al. Current state of CAR-T therapy for T-cell malignancies. Ther Adv Hematol. 2022;13:20406207221143024.","journal-title":"Ther Adv Hematol"},{"issue":"16","key":"584_CR3","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509\u201318.","journal-title":"N Engl J Med"},{"issue":"11","key":"584_CR4","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1038\/s41375-018-0285-8","volume":"32","author":"M Alcantara","year":"2018","unstructured":"Alcantara M, Tesio M, June CH, Houot R. CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells. Leukemia. 2018;32(11):2307\u201315.","journal-title":"Leukemia"},{"issue":"13","key":"584_CR5","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1182\/blood.2023022204","volume":"143","author":"LC Hill","year":"2024","unstructured":"Hill LC, Rouce RH, Wu MJ, Wang T, Ma R, Zhang H, et al. Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed\/refractory mature T-cell lymphomas. Blood. 2024;143(13):1231\u201341.","journal-title":"Blood"},{"issue":"Suppl 1","key":"584_CR6","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1182\/blood-2019-122789","volume":"134","author":"H Zhang","year":"2019","unstructured":"Zhang H, Feng J, Zhang W, Chen Q, Cao Y, Pinz K, et al. First-in-human CD4 CAR clinical trial on peripheral T-cell lymphoma. Blood. 2019;134(Suppl 1):2881.","journal-title":"Blood"},{"issue":"Suppl 1","key":"584_CR7","doi-asserted-by":"publisher","first-page":"10316","DOI":"10.1182\/blood-2022-165971","volume":"140","author":"K Cwynarski","year":"2022","unstructured":"Cwynarski K, Iacoboni G, Tholouli E, Menne TF, Irvine DA, Balasubramaniam N, et al. First in human study of AUTO4, a TRBC1-targeting CAR T-cell therapy in relapsed\/refractory TRBC1-positive peripheral T-cell lymphoma. Blood. 2022;140(Suppl 1):10316\u20137.","journal-title":"Blood"},{"issue":"4","key":"584_CR8","first-page":"321","volume":"140","author":"P Lu","year":"2022","unstructured":"Lu P, Liu Y, Yang J, Zhang X, Yang X, Wang H, et al. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial. Blood. 2022;140(4):321\u201334.","journal-title":"Blood"},{"issue":"Suppl 16","key":"584_CR9","doi-asserted-by":"publisher","first-page":"7002","DOI":"10.1200\/JCO.2023.41.16_suppl.7002","volume":"41","author":"LC Hill","year":"2023","unstructured":"Hill LC, Rouce RH, Smith TS, Boriskie B, Srinivasan M, Thakkar SG, et al. Enhanced anti-tumor activity of CD5 CAR T cells manufactured with tyrosine kinase inhibitors in patients with relapsed\/refractory T-ALL. J Clin Oncol. 2023;41(Suppl 16):7002.","journal-title":"J Clin Oncol"},{"issue":"13","key":"584_CR10","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1158\/1078-0432.CCR-21-4097","volume":"28","author":"M Zhang","year":"2022","unstructured":"Zhang M, Chen D, Fu X, Meng H, Nan F, Sun Z, et al. Autologous nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia\/lymphoma. Clin Cancer Res. 2022;28(13):2830\u201343.","journal-title":"Clin Cancer Res"},{"issue":"30","key":"584_CR11","first-page":"3340","volume":"39","author":"J Pan","year":"2021","unstructured":"Pan J, Tan Y, Wang G, Deng B, Ling Z, Song W, et al. Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human. Phase I Trial J Clin Oncol. 2021;39(30):3340\u201351.","journal-title":"Phase I Trial J Clin Oncol"},{"key":"584_CR12","first-page":"S116","volume":"387816","author":"J Pan","year":"2023","unstructured":"Pan J, Tan Y, Deng B, Ling Z, Xu J, Duan J, et al. Donor-derived CD5 CAR T cells for T-cell acute lymphoblasticleukemia. EHA Libr. 2023;387816:S116.","journal-title":"EHA Libr"},{"issue":"11","key":"584_CR13","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","volume":"32","author":"Y Hu","year":"2022","unstructured":"Hu Y, Zhou Y, Zhang M, Zhao H, Wei G, Ge W, et al. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Res. 2022;32(11):995\u20131007.","journal-title":"Cell Res"},{"issue":"11","key":"584_CR14","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1038\/s41375-023-02018-4","volume":"37","author":"S Li","year":"2023","unstructured":"Li S, Wang X, Liu L, Liu J, Rao J, Yuan Z, et al. CD7 targeted \u201coff-the-shelf\u201d CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies. Leukemia. 2023;37(11):2176\u201386.","journal-title":"Leukemia"},{"issue":"10","key":"584_CR15","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2300709","volume":"389","author":"R Chiesa","year":"2023","unstructured":"Chiesa R, Georgiadis C, Syed F, Zhan H, Etuk A, Gkazi SA, et al. Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia. N Engl J Med. 2023;389(10):899\u2013910.","journal-title":"N Engl J Med"},{"issue":"1","key":"584_CR16","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1186\/s13287-021-02595-0","volume":"12","author":"P Safarzadeh Kozani","year":"2021","unstructured":"Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F. CAR-T cell therapy in T-cell malignancies: is success a low-hanging fruit? Stem Cell Res Ther. 2021;12(1):527.","journal-title":"Stem Cell Res Ther"},{"issue":"8","key":"584_CR17","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","volume":"126","author":"M Mamonkin","year":"2015","unstructured":"Mamonkin M, Rouce RH, Tashiro H, Brenner MK. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood. 2015;126(8):983\u201392.","journal-title":"Blood"},{"issue":"1","key":"584_CR18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ymthe.2022.09.003","volume":"31","author":"N Watanabe","year":"2023","unstructured":"Watanabe N, Mo F, Zheng R, Ma R, Bray VC, van Leeuwen DG, et al. Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies. Mol Ther. 2023;31(1):24\u201334.","journal-title":"Mol Ther"},{"issue":"14","key":"584_CR19","doi-asserted-by":"publisher","first-page":"13459","DOI":"10.1007\/s00432-023-05148-5","volume":"149","author":"J Tang","year":"2023","unstructured":"Tang J, Zhao X. Chimeric antigen receptor T cells march into T cell malignancies. J Cancer Res Clin Oncol. 2023;149(14):13459\u201375.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"8007","key":"584_CR20","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/s41586-024-07233-2","volume":"628","author":"TD Nichakawade","year":"2024","unstructured":"Nichakawade TD, Ge J, Mog BJ, Lee BS, Pearlman AH, Hwang MS, et al. TRBC1-targeting antibody-drug conjugates for the treatment of T cell cancers. Nature. 2024;628(8007):416\u201323.","journal-title":"Nature"},{"issue":"1","key":"584_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41408-023-00822-w","volume":"13","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Li C, Du M, Jiang H, Luo W, Tang L, et al. Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies. Blood Cancer J. 2023;13(1):61.","journal-title":"Blood Cancer J"},{"issue":"Suppl 1","key":"584_CR22","doi-asserted-by":"publisher","first-page":"3480","DOI":"10.1182\/blood-2023-182538","volume":"142","author":"L Zhao","year":"2023","unstructured":"Zhao L, Zhou Q, Chen C, Ling Z, Wang K, Wu F, et al. CAR T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia\/lymphoma: a retrospective study. Blood. 2023;142(Suppl 1):3480.","journal-title":"Blood"},{"issue":"8","key":"584_CR23","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1158\/1078-0432.CCR-22-2924","volume":"29","author":"W Chen","year":"2023","unstructured":"Chen W, Shi H, Liu Z, Yang F, Liu J, Zhang L, et al. Single-cell transcriptomics reveals immune reconstitution in patients with R\/R T-ALL\/LBL treated with donor-derived CD7 CAR-T therapy. Clin Cancer Res. 2023;29(8):1484\u201395.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"584_CR24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","volume":"32","author":"ML Schubert","year":"2021","unstructured":"Schubert ML, Schmitt M, Wang L, Ramos CA, Jordan K, Muller-Tidow C, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021;32(1):34\u201348.","journal-title":"Ann Oncol"},{"issue":"1","key":"584_CR25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-023-01427-3","volume":"16","author":"Y Tan","year":"2023","unstructured":"Tan Y, Shan L, Zhao L, Deng B, Ling Z, Zhang Y, et al. Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia. J Hematol Oncol. 2023;16(1):34.","journal-title":"J Hematol Oncol"},{"issue":"16","key":"584_CR26","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","volume":"390","author":"Y Hu","year":"2024","unstructured":"Hu Y, Zhang M, Yang T, Mo Z, Wei G, Jing R, et al. Sequential CD7 CAR T-cell therapy and allogeneic HSCT without GVHD prophylaxis. N Engl J Med. 2024;390(16):1467\u201380.","journal-title":"N Engl J Med"},{"key":"584_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03228-8","author":"BLZ Oh","year":"2024","unstructured":"Oh BLZ, Shimasaki N, Coustan-Smith E, Chan E, Poon L, Lee SHR, et al. Fratricide-resistant CD7-CAR T cells in T-ALL. Nat Med. 2024. https:\/\/doi.org\/10.1038\/s41591-024-03228-8.","journal-title":"Nat Med"},{"issue":"3","key":"584_CR28","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1089\/rej.2007.0612","volume":"11","author":"G Rappl","year":"2008","unstructured":"Rappl G, Schrama D, Hombach A, Meuer EK, Schmidt A, Becker JC, et al. CD7(-) T cells are late memory cells generated from CD7(+) T cells. Rejuvenation Res. 2008;11(3):543\u201356.","journal-title":"Rejuvenation Res"},{"key":"584_CR29","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.149819","author":"MY Kim","year":"2021","unstructured":"Kim MY, Cooper ML, Jacobs MT, Ritchey JK, Hollaway J, Fehniger TA, et al. CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy. JCI Insight. 2021. https:\/\/doi.org\/10.1172\/jci.insight.149819.","journal-title":"JCI Insight"},{"issue":"25","key":"584_CR30","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1182\/blood.2021015020","volume":"140","author":"A Freiwan","year":"2022","unstructured":"Freiwan A, Zoine JT, Crawford JC, Vaidya A, Schattgen SA, Myers JA, et al. Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies. Blood. 2022;140(25):2684\u201396.","journal-title":"Blood"},{"issue":"10","key":"584_CR31","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1631\/jzus.B2200256","volume":"23","author":"T Gu","year":"2022","unstructured":"Gu T, Zhu M, Huang H, Hu Y. Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches. J Zhejiang Univ Sci B. 2022;23(10):793\u2013811.","journal-title":"J Zhejiang Univ Sci B"},{"issue":"12","key":"584_CR32","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1002\/ajh.27094","volume":"98","author":"X Zhang","year":"2023","unstructured":"Zhang X, Yang J, Li J, Qiu L, Zhang J, Lu Y, et al. Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy. Am J Hematol. 2023;98(12):1898\u2013908.","journal-title":"Am J Hematol"},{"issue":"Suppl 1","key":"584_CR33","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1182\/blood-2023-185696","volume":"142","author":"X Cao","year":"2023","unstructured":"Cao X, Zhang J, Lu Y, Zhao Y, Liu D, Xiong M, et al. A parallel comparison of the safety and efficacy of allogeneic hematopoietic stem cell transplantation for refractory and relapsed T-ALL\/Lbl patients who achieved complete remission with CD7 CAR-T versus patients who achieved first complete remission with chemotherapy before transplantation. Blood. 2023;142(Suppl 1):3611.","journal-title":"Blood"},{"issue":"Suppl 1","key":"584_CR34","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1182\/blood-2023-180834","volume":"142","author":"Z Li","year":"2023","unstructured":"Li Z, Zheng Q, Yang K, Xu T, Wang L, Wang X, et al. CD7 chimeric antigen receptor T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation remarkably improved long-term disease-free survival in refractory\/relapsed T-cell acute lymphoblastic leukemia\/lymphoma. Blood. 2023;142(Suppl 1):239.","journal-title":"Blood"},{"key":"584_CR35","doi-asserted-by":"publisher","first-page":"1170968","DOI":"10.3389\/fimmu.2023.1170968","volume":"14","author":"J Liu","year":"2023","unstructured":"Liu J, Zhang Y, Guo R, Zhao Y, Sun R, Guo S, et al. Targeted CD7 CAR T-cells for treatment of T-lymphocyte leukemia and lymphoma and acute myeloid leukemia: recent advances. Front Immunol. 2023;14:1170968.","journal-title":"Front Immunol"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-024-00584-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-024-00584-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-024-00584-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T12:08:52Z","timestamp":1732795732000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-024-00584-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["584"],"URL":"https:\/\/doi.org\/10.1186\/s40164-024-00584-6","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"assertion":[{"value":"29 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"117"}}